WikiAdmin am 9. Februar 2020 um 10:45 Uhr

2020-02-09T10:45:53Z

← Nächstältere Version		Version vom 9. Februar 2020, 10:45 Uhr
Zeile 1:		Zeile 1:
	~~{{NYT en}}~~		'''HP802-247''' ist eine experimentelle Sprühbehandlung für venöse Beingeschwüre. Der mögliche Wert dieses Sprays besteht darin, dass es Personen behandeln kann, deren Haut mit einer herkömmlichen Behandlung (wie Kompressionsverbände und -verbände) nicht heilt und für die die einzige Alternative eine Hauttransplantation wäre.<ref>{{REFweb
	'''HP802-247''' ~~is an experimental spray treatment for venous leg ulcers~~. ~~The potential value of this spray is that it could treat those people whose skin will not heal with conventional treatment~~ (~~such as compression bandages and dressings~~)~~, and for whom the only alternative option could be skin graft~~.<ref>{{REFweb
	~~\|last=~~
	~~\|first=~~
	\|date=2012-08-03		\|date=2012-08-03
	\|title=Spray-on-skin' treatment for leg ulcers		\|title=Spray-on-skin' treatment for leg ulcers
Zeile 11:		Zeile 8:

	== HP802-247 ==		== HP802-247 ==
	~~The new spray~~ (HP802-247) ~~consisted of a combination of donated skin cells and proteins~~.		Das neue Spray (HP802-247) bestand aus einer Kombination von gespendeten Hautzellen und Proteinen.

	~~The study was conducted by researchers from the~~ University of Miami ~~and other institutions~~ in ~~the US and was funded by~~ Healthpoint Biotherapeutics, ~~a biotech company that specialises in wound care products~~. ~~The study was published~~ in ~~the peer-reviewed medical journal~~ The Lancet.<ref>{{REFweb		Die Studie wurde von Forschern der University of Miami und anderer Einrichtungen in den USA durchgeführt und von Healthpoint Biotherapeutics, einem auf Wundversorgungsprodukte spezialisierten Biotech-Unternehmen, finanziert. Die Studie wurde in der Fachzeitschrift ''The Lancet'' veröffentlicht.<ref>{{REFweb
	\|last=		\|last=
	\|first=		\|first=
Zeile 23:		Zeile 20:
	}}</ref>		}}</ref>

	~~The new treatment is a form of cell treatment applied as a spray~~. ~~It contains keratinocytes~~, ~~which are the main cell type~~ in ~~the outer layer of the skin~~, ~~and fibroblasts~~, ~~a cell type found in connective tissue~~. ~~These cells had been grown in the laboratory and were originally derived from newborn foreskin samples~~ (~~removed during circumcision~~). ~~This was a phase~~ 2 ~~trial that aimed to see whether the new treatment was effective and safe~~, ~~and to find out the best dose to use~~. ~~If the results of phase~~ 2 ~~trials are positive~~ (~~as these trial results were~~) ~~they will usually be followed by larger phase~~ 3 ~~trials~~.		Die neue Behandlung ist eine Form der Zellbehandlung, die als Spray angewendet wird. Es enthält Keratinozyten, die den Hauptzelltyp in der äußeren Hautschicht darstellen, und Fibroblasten, einen im Bindegewebe vorkommenden Zelltyp. Diese Zellen wurden im Labor gezüchtet und stammten ursprünglich aus neugeborenen Vorhäuten (die während der Beschneidung entfernt wurden). Hierbei handelte es sich um eine Phase-2-Studie, in der untersucht werden sollte, ob die neue Behandlung wirksam und sicher ist und welche Dosis am besten geeignet ist. Wenn die Ergebnisse von Phase-2-Studien positiv sind (so wie diese Studienergebnisse), folgen normalerweise größere Phase-3-Studien.

	{{REF}}		{{REF}}

WikiAdmin: Die Seite wurde neu angelegt: „{{NYT en}} '''HP802-247''' is an experimental spray treatment for venous leg ulcers. The potential value of this spray is that it could treat those people whos…“

2019-11-22T21:24:10Z

Die Seite wurde neu angelegt: „{{NYT en}} '''HP802-247''' is an experimental spray treatment for venous leg ulcers. The potential value of this spray is that it could treat those people whos…“

Neue Seite

{{NYT en}}
'''HP802-247''' is an experimental spray treatment for venous leg ulcers. The potential value of this spray is that it could treat those people whose skin will not heal with conventional treatment (such as compression bandages and dressings), and for whom the only alternative option could be skin graft.<ref>{{REFweb
|last=
|first=
|date=2012-08-03
|title=Spray-on-skin' treatment for leg ulcers
|url=http://www.nhs.uk/news/2012/08august/pages/spray-on-skin-treatment-for-leg-ulcers.aspx
|publisher=NHS
|accessdate=2012-11-24
}}</ref>

== HP802-247 ==
The new spray (HP802-247) consisted of a combination of donated skin cells and proteins.

The study was conducted by researchers from the University of Miami and other institutions in the US and was funded by Healthpoint Biotherapeutics, a biotech company that specialises in wound care products. The study was published in the peer-reviewed medical journal The Lancet.<ref>{{REFweb
|last=
|first=
|date=201209
|title=Spray-applied cell therapy with human allogeneic fibroblasts and keratinocytes for the treatment of chronic venous leg ulcers: a phase 2, multicentre, double-blind, randomised, placebo-controlled trial
|url=http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60644-8/abstract
|publisher=The Lancet
|accessdate=2012-11-24
}}</ref>

The new treatment is a form of cell treatment applied as a spray. It contains keratinocytes, which are the main cell type in the outer layer of the skin, and fibroblasts, a cell type found in connective tissue. These cells had been grown in the laboratory and were originally derived from newborn foreskin samples (removed during circumcision). This was a phase 2 trial that aimed to see whether the new treatment was effective and safe, and to find out the best dose to use. If the results of phase 2 trials are positive (as these trial results were) they will usually be followed by larger phase 3 trials.

{{REF}}

[[Kategorie:Vorhaut-Produkte]]
[[Kategorie:Finanzieller Vorteil]]

[[Kategorie:Von CircLeaks]]
[[Kategorie:Von IntactWiki]]

[[en:{{FULLPAGENAME}}]]

HP802-247 - Versionsgeschichte

WikiAdmin am 9. Februar 2020 um 10:45 Uhr

WikiAdmin: Die Seite wurde neu angelegt: „{{NYT en}} '''HP802-247''' is an experimental spray treatment for venous leg ulcers. The potential value of this spray is that it could treat those people whos…“